Overview

This strain has been discontinued. Please see Stock No. 025184.

Genetic overview

Genetic Background	Generation

Egfr^wa2

Allele Type	Gene Symbol	Gene Name
Spontaneous	Egfr	epidermal growth factor receptor

Allele Type	Gene Symbol	Gene Name
Spontaneous	a	nonagouti

Research Applications

Cancer Research
Dermatology Research
Developmental Biology Research
Endocrine Deficiency Research
Immunology, Inflammation and Autoimmunity Research
Neurobiology Research

View All Research Applications

Details

Detailed Description

Mice homozygous mice for the waved 2 spontaneous mutation (Egfr^wa2) are recognizable at 2 to 3 days by curly whiskers. The first coat is waved but later coats are not; vibrissae usually remain curled and the guard hairs curved. Some homozygotes have eyelids open at birth. Fertile mutant females have impaired lactation.

Development

In 1933, or shortly thereafter, the waved 2 mutation arose spontaneously in the "abnormal Corpus callosum stock" held by Dr. Clyde Keeler at The Bussey Institute of Harvard Medical School. In 1935 waved 2 (Egfr^wa2) was received from Dr. Reed by Dr. G.D. Snell at the Jackson Laboratory. It was crossed to shaker 2 (Myo15^sh2) mice of Dr. C.C. Little at The Jackson Laboratory and waved 2 shaker 2 (Egfr^wa2 Myo15^sh2) mice were crossed to flexed-tail (f) mice received from the Bussey Institute in 1936. All three mutations were maintained in this stock. In 1947 this stock was returned after the fire to Dr. Snell from Dr. Walter Heston. The stock was maintained by non-sibling within-stock matings until 1960 when one outcross was made to C3H/HeJ. The stock was then sibling mated for 13 generations before 3 crosses were made to C57BL/6J, via backcross-intercross, and the stock was then non-sibling within-stock mated and in 1969 two lines were selected, Myo15^sh2 and Egfr^wa2 and flexed was dropped from these lines. In the Egfr^wa2 line a cross was made to B6.Cg-bc, a congenic strain then at N5, and the resulting stock, carrying a and Egfr^wa2 but not bc, was sibling mated to maintain Egfr^wa2 by forced heterozygosis. It was cryopreserved in 1986 with the common parent at F53.

Control Suggestions

Untyped from the colony

Additional Information

Considerations for Choosing Controls

Genetics

Egfr^wa2

Allele Symbol: Egfr^wa2

Allele Name	waved 2
Allele Type	Spontaneous
Allele Synonym(s)	wa2; wa-2; waved2
Gene Symbol and Name	Egfr, epidermal growth factor receptor
Gene Synonym(s)
Strain of Origin	STOCK ac
Chromosome	11
General Note	Found by Keeler in an ``abnormal corpus callosum'' stock at the Bussey Institution.
Molecular Note	A T-to-G transversion mutation in the sequences encoding the tyrosine kinase domain results in a substitution of a highly conserved valine with glycine at position 767 (P.V767G) in the third kinase subdomain.

a

Allele Symbol: a

Allele Name	nonagouti
Allele Type	Spontaneous
Allele Synonym(s)
Gene Symbol and Name	a, nonagouti
Gene Synonym(s)
Strain of Origin	old mutant of the mouse fancy
Chromosome	2
General Note	Insertion of the LV30 retrotransposon without the beta4 retrovirus sequence does not cause the nonagouti phenotype. J:278039
Molecular Note	Characterization of this allele shows an insertion of DNA comprised of a 5.5kb virus-like element, VL30, into the first intron of the agouti gene. The VL30 element itself contains an additional 5.5 kb sequence, flanked by 526 bp of direct repeats (beta4 retroviral sequence). The host integration site is the same as for a^t-2Gso and A^w-38J and includes a duplication of four nucleotides of host DNA and a deletion of 2 bp from the end of each repeat. Northern analysis of mRNA from skin of homozygotes shows a smaller agouti message and levels 8 fold lower than found in wild-type.

Disease/Phenotype

Disease Terms

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

aortic valve disease

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Genotype: Egfr^wa2 related

Cancer Research
- Growth Factors/Receptors/Cytokines
Dermatology Research
- Skin and Hair Texture Defects
Developmental Biology Research
- Neural Tube Defects
Endocrine Deficiency Research
- Skin Defects
Immunology, Inflammation and Autoimmunity Research
- Growth Factors/Receptors/Cytokines
Neurobiology Research
- Neural Tube Defects

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Egfr^wa2/Egfr^wa2
B6EiC3Sn a/A-Egfr Wnt3a/J

cardiovascular system phenotype

enlarged aortic valve
- enlarged/thickened aortic valves

thick aortic valve

endocrine/exocrine gland phenotype

abnormal lactation
- reduction of milk within ducts of mammary glands and secretory vacuolation within lobules is less pronounced

abnormal mammary gland morphology
- small mammary glands and the ratio of gland to adipose tissue is reduced

integument phenotype

abnormal hair texture

abnormal lactation
- reduction of milk within ducts of mammary glands and secretory vacuolation within lobules is less pronounced

abnormal mammary gland morphology
- small mammary glands and the ratio of gland to adipose tissue is reduced

abnormal vibrissa morphology

Genotype: Egfr^wa2/Egfr^wa2
involves: C57BL/6

cardiovascular system phenotype

abnormal aorta morphology
- aortic diameters at the level of the sinuses of Valsalva and at the level of the proximal ascending aorta are increased at all ages
- aortic enlargement at 1.5 months of age

abnormal aortic valve morphology
- alpha-smooth muscle actin levels are elevated in aortic valves at 6 and 12 months of age but not at 1.5 months, indicating transdifferentiation of valve interstitial cells from a quiescent state to a profibrotic state
- aortic valve collagen levels are normal at 1.5 months of age but are increased at 6 and 12 months of age
- Normal - however, levels of biglycan are normal
- intact versican is increased while cleaved versican is reduced in aortic valves at 6 months of age indicating increased levels of total proteoglycan
- levels of proteoglycan in the aortic valve are elevated at 1.5, 6, and 12 months of age
- lipid levels are increased in aortic valves at 6 and 12 months of age but not at 1.5 months
- pioglitazone treatment has no effect on collagen levels, on aortic valve lipid levels, on aortic valve alpha-smooth muscle actin levels, or on intact or cleaved versican levels

abnormal heart left ventricle morphology
- left ventricle mass, indexed to body mass, is elevated at 1.5, 6, and 12 months of age
- pioglitazone treatment has no effect on left ventricle mass

abnormal heart valve physiology
- an increase in apoptosis in the aortic valve is seen at 6 and 12 months of age, but not at 1.5 months
- elevation of transvalvular gradients in aortic valves
- Normal - treatment with pioglitazone prevents increases in apoptosis

abnormal myocardial fiber morphology
- myocardial transverse tubule organization is disrupted at 12 months of age but not at 1.5 and 3 months

aortic valve regurgitation
- all mice with aortic stenosis also have severe aortic regurgitation with diastolic prolapse of more than or equal to 1 valve cusps into the left ventricular outflow tract
- Normal - however, mitral regurgitation is absent
- pioglitazone treatment has no effect on prevalence of aortic regurgitation
- prevalence of moderate or severe aortic regurgitation is 70%, 81%, and 73% at 1.5, 6, and 12 months of age, respectively

aortic valve stenosis
- 3 of 55 mice show an aortic cup separation of <0.66 mm, indicating a low level of aortic stenosis
- Normal - aortic cusp separation is normal in most mice and aortic cusp movement is symmetrical at all ages

calcified aortic valve
- aortic valve calcification is increased at 6 and 12 months of age but not at 1.5 months
- marker analysis indicates osteogenic transformation in the aortic valve at 6 and 12 months of age but not at 1.5 months
- pioglitazone treatment reduces valve calcification

cardiac fibrosis
- fibrosis is evident in the myocardium at 12 months of age

decreased ventricle muscle contractility
- by 12 months of age, a trend toward greater left ventricular dilation and lower left ventricle ejection fraction in females than in males
- left ventricle ejection fraction is decreased by 12 months of age but not at 1.5 and 6 months of age
- right ventricle ejection fraction is decreased at 6 months of age

heart left ventricle hypertrophy
- left ventricle hypertrophy at 1.5 and 3 months of age, at a time when left ventricle systolic function is normal

increased cardiac stroke volume
- Normal - however, stroke volume is not increased in the 30% of mice that do not have aortic regurgitation at 1.5 months of age
- left ventricle stroke volume is increased at 1.5, 6, and 12 months of age
- pioglitazone treatment has no effect on left ventricle stroke volume

increased heart left ventricle size
- left ventricle chamber enlargement at 1.5, 6, and 12 months of age

increased pulse pressure
- increase in transvalvular gradients associated with increased aortic pulse pressure

growth/size/body region phenotype

heart left ventricle hypertrophy
- left ventricle hypertrophy at 1.5 and 3 months of age, at a time when left ventricle systolic function is normal

muscle phenotype

abnormal myocardial fiber morphology
- myocardial transverse tubule organization is disrupted at 12 months of age but not at 1.5 and 3 months

decreased ventricle muscle contractility
- by 12 months of age, a trend toward greater left ventricular dilation and lower left ventricle ejection fraction in females than in males
- left ventricle ejection fraction is decreased by 12 months of age but not at 1.5 and 6 months of age
- right ventricle ejection fraction is decreased at 6 months of age

heart left ventricle hypertrophy
- left ventricle hypertrophy at 1.5 and 3 months of age, at a time when left ventricle systolic function is normal

The following phenotype relates to a compound genotype created using this strain

Genotype: Egfr^wa2/Egfr^wa2
STOCK ac

growth/size/body region phenotype

decreased body size

vision/eye phenotype

abnormal eye morphology
- Background Sensitivity - a squint and/or cataract phenotype occurs in this genotype with penetrance of 81 percent

cataract

integument phenotype

abnormal hair cortex keratinization
- cortex of hair shaft is thickened

abnormal hair medulla
- hairs have irregularities and narrowing of the medulla

curly vibrissae
- vibrissae are bent upon the second day and are distinctly curled by 4-5 days of age
- vibrissae remain curled event though coat waviness decreases or disappears

increased curvature of guard hairs
- guard hairs remain curved even though coat waviness decreases over time
- when coat is most waved, the guard hairs are frizzled

increased curvature of hairs
- occurs where the medulla is irregular and narrowed

short hair
- coat length remains shorter

short vibrissae

waved hair
- aggregation chimeras between Egfr^wa2/Egfr^wa2 and +/+ embryos result in a patchy distribution of waved and normal hair, suggesting that Egfr^wa2 acts locally in the hair follicle cells
- coat waviness increases from 4th to 6th weeks of age but decreases during 7-8 weeks of age
- waviness may disappear entirely or may be evident to a slight degree throughout life
- waviness of hair appears as soon as the coat develops, at 7-8 days of age

Genotype: Egfr^wa2/Egfr^wa2
STOCK Egfr

cardiovascular system phenotype

abnormal aortic valve morphology
- aortic valve size ranges from unaffected to mildly or markedly thickened

abnormal semilunar valve morphology
- about 80% exhibit semilunar valve enlargement

aortic valve regurgitation
- valve abnormalities persist into adulthood causing moderate to severe regurgitation

increased left ventricle systolic pressure
- higher peak left ventricular systolic pressure and a trend towards increased +dP/dT

prolonged PR interval

prolonged RR interval

References

Additional References

Luetteke NC; Phillips HK; Qiu TH; Copeland NG; Earp HS; Jenkins NA; Lee DC. 1994. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase. Genes Dev 8(4):399-413PubMed: 8125255 MGI: J:16986

Additional - a related

Additional - Egfr^wa2 related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Sanger sequencing:Egfr-Alternate 1
- Genotyping resources and troubleshooting

Terms Of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Genetic overview

Research Applications

Detailed Description

Development

Control Suggestions

Additional Information

Egfrwa2

Allele Symbol: Egfrwa2

a

Allele Symbol: a

Disease Terms

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Genotype: Egfrwa2 related

Mammalian Phenotype Terms by Genotype

Genotype: Egfrwa2/Egfrwa2B6EiC3Sn a/A-Egfr Wnt3a/J

cardiovascular system phenotype

endocrine/exocrine gland phenotype

integument phenotype

Genotype: Egfrwa2/Egfrwa2involves: C57BL/6

cardiovascular system phenotype

growth/size/body region phenotype

muscle phenotype

Genotype: Egfrwa2/Egfrwa2STOCK ac

growth/size/body region phenotype

vision/eye phenotype

integument phenotype

Genotype: Egfrwa2/Egfrwa2STOCK Egfr

cardiovascular system phenotype

References

Additional References

Additional - a related

Additional - Egfrwa2 related

Genotyping Protocols

Terms Of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Egfr^wa2

Allele Symbol: Egfr^wa2

Genotype: Egfr^wa2 related

Genotype: Egfr^wa2/Egfr^wa2
B6EiC3Sn a/A-Egfr Wnt3a/J

Genotype: Egfr^wa2/Egfr^wa2
involves: C57BL/6

Genotype: Egfr^wa2/Egfr^wa2
STOCK ac

Genotype: Egfr^wa2/Egfr^wa2
STOCK Egfr

Additional - Egfr^wa2 related